Albert David Limited (NSE: ALBERTDAVD | BSE: 524013)
Source: Albert David Limited Annual Report FY 2025-26 (Fiscal Year Ended March 31, 2026) 📊 Stock Screeners
Albert David Limited (ADL) is a prominent Indian pharmaceutical entity headquartered in Kolkata, West Bengal. Established over eight decades ago, the company has built clinical trust across therapeutic segments including parenteral formulations, small and large volume infusion solutions (IV fluids), oral liquids, herbal formulations, vision care products, and active pharmaceutical ingredients (APIs).
- Placentrex Portfolio: Human placenta extract-based regenerative formulation marketed as injections, topical gels, and creams. The Kolkata manufacturing plant produced over 91 Lakh total units across the Placentrex portfolio in FY 2025-26.
- Parenterals & Infusions: High-volume parenteral solutions (IV fluids in plastic and glass containers) produced at the Ghaziabad unit, alongside specialized small-volume parenterals such as Alamin SN (amino acid infusions).
- Neglected Tropical Diseases (Kala-Azar): Albert David is a key manufacturer of Sodium Stibogluconate (SSG) injection used in the treatment of Leishmaniasis (Kala-Azar). In FY 2025-26, the company advanced R&D and commercial production of Miltefosine, an oral anti-leishmaniasis API and capsule formulation complying with WHO specifications.
- Customer Concentration: The company maintains a diversified prescribers and stockists network. Its single largest customer accounted for 5.04% of total revenue in FY 2025-26 (compared to 12.16% in FY 2024-25). Institutional supplies to central and state government healthcare departments accounted for ₹30.66 Crores (9.31% of sales) in FY 2025-26, up from ₹0.56 Crores (1.64%) in FY 2024-25.
📋 Quick Facts / Company Snapshot: Albert David Limited (NSE: ALBERTDAVD | BSE: 524013)
| Attribute | Disclosed Detail |
|---|---|
| Official Company Name | Albert David Limited |
| Corporate Identity Number (CIN) | L51109WB1938PLC009490 |
| ISIN | INE155C01010 |
| Stock Exchange Listing | BSE Limited (Scrip Code: 524013) & National Stock Exchange of India Limited (Symbol: ALBERTDAVD) |
| Date of Incorporation / Founding Year | November 16, 1938 (87 Years of Operations) |
| Registered Office & Corporate Headquarters | ‘D’ Block, 3rd Floor, Gillander House, 8, Netaji Subhas Road, Kolkata – 700 001, West Bengal, India |
| Telephone & Official IR Email | Tel: +91-33-2262-8456 / 8492 | Email: albertdavid@adlindia.in / adlcorp.secretary@adlindia.in |
| Executive Chairman | Mr. Arun Kumar Kothari (DIN: 00051900) |
| Chief Executive Officer (CEO) | Mr. Amit Mahla (Appointed CEO w.e.f. May 12, 2026; Whole-time Director & CEO w.e.f. June 19, 2026) |
| Chief Financial Officer (CFO) | Mr. Ranadeep Bhattacharya |
| Company Secretary & Compliance Officer | Mr. Lalit Lohia (ACS – 23995) |
| Promoter & Holding Group | Kothari Group (Flagship Pharmaceutical Enterprise) |
| Industry / Sector Classification | Pharmaceuticals & Biotechnology (Formulations, Infusion Solutions, Herbal Products & APIs) |
| Total Workforce Strength | 1,476 Permanent Employees (approx. 1,500 total workforce) |
| Manufacturing Facilities | 2 Units: Kolkata (West Bengal) & Ghaziabad (Uttar Pradesh) |
| Credit Ratings & Rating Agency | CARE Ratings: Long-Term Facilities rated CARE A (Stable) | Short-Term Facilities rated CARE A1 |
| Statutory Auditors | M/s. L. B. Jha & Co., Chartered Accountants, Kolkata (FRN: 301088E/E300295) |
| Secretarial Auditors | M/s. MKB & Associates, Practicing Company Secretaries, Kolkata |
| Cost Auditors | M/s. S. Gupta & Company, Cost Accountants, Kolkata (FRN: 000020) |
| Internal Auditors | PricewaterhouseCoopers Services LLP, Salt Lake, Kolkata |
| Registrar & Share Transfer Agent (RTA) | Maheshwari Datamatics Pvt. Ltd., 23, R.N. Mukherjee Road, 5th Floor, Kolkata – 700 001 |
🏢 The Corporate Identity: Albert David Overview, Promoters & History
The Big Picture: Business Model & Core Value Proposition
Albert David Limited (ADL) is a prominent Indian pharmaceutical entity headquartered in Kolkata, West Bengal. Established over eight decades ago, the company has built clinical trust across therapeutic segments including parenteral formulations, small and large volume infusion solutions (IV fluids), oral liquids, herbal formulations, vision care products, and active pharmaceutical ingredients (APIs). As the flagship company of the diversified Kothari Group, Albert David combines legacy manufacturing infrastructure with targeted research and development to serve domestic pharmacies, stockists, medical specialists, state healthcare institutions, and international healthcare organisations.
The company’s commercial model rests on a dual foundation of high-volume essential healthcare products and proprietary therapeutic platforms. Its core growth engine is driven by Placentrex, a biologically active human placental extract formulation pioneered in India by Albert David. Placentrex accounts for over 30% of the company’s annual revenue, establishing an unmatched position in tissue regeneration, non-healing chronic wound care, burns, and pelvic inflammatory conditions. Operating through a lean distributor network of approximately 2,500 stockists across India, Albert David also maintains an international footprint spanning Southeast Asia, Africa, the Middle East, and Latin America.
The Founders, Promoters & Their Legacy
Albert David Limited belongs to the industrial house of Kolkata, the Kothari Group. The promoter family’s enterprise spans tea, engineering, textiles, chemicals, and pharmaceuticals. The leadership of the promoter group is anchored by Executive Chairman Mr. Arun Kumar Kothari, son of Late G. D. Kothari. With over three decades of leadership at Albert David, Mr. Kothari has guided the company’s capital allocation, facility modernisations, and research alliances.
The promoter group collectively holds a 62.24% equity stake in Albert David Limited as of March 31, 2026. Key promoter entities and family members include:
- Kothari Investment & Industries Private Limited: Holds 23,60,531 equity shares (41.36% of total equity).
- Mr. Anand Vardhan Kothari: Non-Executive Director, holding 5,66,500 equity shares (9.93%).
- M.D. Kothari & Company Limited: Holds 3,94,700 equity shares (6.92%).
- Kothari Phytochemicals & Industries Limited: Holds 99,200 equity shares (1.74%).
- Mr. Arun Kumar Kothari: Executive Chairman, holding 1,12,000 equity shares (1.96%).
- Mrs. Prabhawati Devi Kothari: Non-Executive Director, holding 17,527 equity shares (0.31%).
The Journey: Corporate History & Key Milestones
Albert David Limited was incorporated on November 16, 1938, in Kolkata, laying the groundwork for eight decades of pharmaceutical manufacturing in India. Over its history, the company transitioned from standard galenicals and basic formulations to advanced parenterals, large volume parenterals (LVP), and proprietary tissue-extract formulations.
The historical trajectory of Albert David is marked by key operational and scientific milestones:
- 1938 (Foundation): Incorporation of Albert David Limited in Kolkata, establishing pharmaceutical manufacturing capabilities in eastern India.
- Placentrex Research Era: Pioneered placental extract research in India, formulating Placentrex injection, gel, and cream for tissue repair, chronic wound healing, and anti-inflammatory therapies.
- Facility Expansion & Certification: Established a modern Small Volume Parenteral (SVP) suite at the Kolkata unit and an ISO 9001:2015 certified production plant in Ghaziabad, Uttar Pradesh, for large volume parenterals and oral liquids.
- FY 2021–FY 2025 (The R&D Pivot): Scaled annual R&D expenditure from ₹1.95 Crores to ₹2.89 Crores to isolate, map, and validate bio-active peptides and nucleotides within human placental extract.
- FY 2026 (Scientific Milestone & Acceleration): Collaborated with the Department of Biotechnology at Indian Institute of Technology (IIT) Kharagpur to map specific nucleotides and peptides responsible for Placentrex’s therapeutic efficacy. Completed facility upgrades in compliance with Revised Schedule M standards and successfully passed the WHO-Geneva Prequalification (PQ) audit for Sodium Stibogluconate (SSG) injection.
The Corporate Umbrella & Group Structure
Albert David Limited operates as a standalone operating company without any subsidiaries, associates, or joint ventures. All operational divisions, manufacturing plants, R&D centers, and sales depots report directly to the central management structure headquartered in Kolkata.
⚙️ The Business Engine: Albert David Segments, Brands, Products & Operations
The Core Divisions & Segment Revenue Breakdown
Albert David Limited operates under a single primary business segment: Pharmaceuticals. In accordance with Ind AS 108, the company’s management evaluates performance across product categories and geographical distribution rather than separate operating divisions.
| Product Category | FY 2025-26 Revenue (₹ in Crores) | % Share of Total Revenue | FY 2024-25 Revenue (₹ in Crores) | % Share of Total Revenue | Latest YoY (%) |
|---|---|---|---|---|---|
| Large Volume Parenterals (LVP / IV Fluids) | 101.51 | 30.82% | 95.81 | 27.91% | +5.95% |
| Small Volume Parenterals (SVP / Injections) | 72.33 | 21.96% | 51.31 | 14.95% | +40.97% |
| Syrups & Oral Liquids | 55.49 | 16.85% | 72.64 | 21.16% | -23.61% |
| Tablets | 35.45 | 10.76% | 54.81 | 15.97% | -35.32% |
| Ointments & Topicals | 31.14 | 9.45% | 31.11 | 9.06% | +0.10% |
| Capsules | 30.72 | 9.33% | 33.14 | 9.65% | -7.30% |
| Others (Vision Care / APIs / Scrap) | 2.73 | 0.83% | 4.42 | 1.29% | -38.24% |
| Total Revenue from Sale of Goods | 329.36 | 100.00% | 343.25 | 100.00% | -4.05% |
The Product & Service Catalog (with Operational KPIs, Order Book & Customer Concentration)
Albert David’s product line covers acute and chronic therapeutic areas, including regenerative medicine, gastroenterology, hepatology, anti-infectives, clinical nutrition, laxatives, and metabolic health. Key operational metrics and commercial traits include:
- Placentrex Portfolio: Human placenta extract-based regenerative formulation marketed as injections, topical gels, and creams. The Kolkata manufacturing plant produced over 91 Lakh total units across the Placentrex portfolio in FY 2025-26.
- Parenterals & Infusions: High-volume parenteral solutions (IV fluids in plastic and glass containers) produced at the Ghaziabad unit, alongside specialized small-volume parenterals such as Alamin SN (amino acid infusions).
- Neglected Tropical Diseases (Kala-Azar): Albert David is a key manufacturer of Sodium Stibogluconate (SSG) injection used in the treatment of Leishmaniasis (Kala-Azar). In FY 2025-26, the company advanced R&D and commercial production of Miltefosine, an oral anti-leishmaniasis API and capsule formulation complying with WHO specifications.
- Customer Concentration: The company maintains a diversified prescribers and stockists network. Its single largest customer accounted for 5.04% of total revenue in FY 2025-26 (compared to 12.16% in FY 2024-25). Institutional supplies to central and state government healthcare departments accounted for ₹30.66 Crores (9.31% of sales) in FY 2025-26, up from ₹0.56 Crores (1.64%) in FY 2024-25.
- Raw Material Sourcing: Raw materials and packing supplies are sourced through indigenous vendors and selective international suppliers. In FY 2025-26, total foreign currency expenditure on raw materials, components, and capital imports stood at ₹25.08 Crores.
The Names You Know: Key Brands & Flagship Portfolio
| Brand / Product Name | Category / Business Segment | Target Market & Key Positioning |
|---|---|---|
| Placentrex (Inj / Gel / Cream) | Regenerative Medicine / Parenteral & Topical | Flagship brand derived from human placental extract; prescribed for non-healing chronic wounds, pelvic inflammatory disease, burn wound care, and tissue repair. |
| Alamin SN | Clinical Nutrition / Small Volume Parenteral | Essential amino acid parenteral infusion used in critical care, post-operative recovery, and severe nutritional deficiencies. |
| Alamin-M Forte | Nutraceuticals / Oral Solid Dosage | Multivitamin and amino acid combination capsule prescribed for metabolic support, weakness, and convalescence. |
| Evict Group | Gastroenterology / Oral Liquid | Lactulose-based laxative syrup formulation prescribed for chronic constipation and hepatic encephalopathy management. |
| Sioplex-L | Nutritional Supplements / Oral Syrup | B-complex syrup enriched with L-Lysine for appetite stimulation and nutritional deficiency corrections. |
| Adliv Syrup | Hepatology / Herbal Formulation | Herbal liver tonic syrup indicated for hepatic disorders, fatty liver, and liver function restoration. |
| Cyp-L Syrup | Pediatric & Adult Nutrition / Oral Liquid | Cyproheptadine and L-lysine combination syrup for appetite enhancement and weight gain support. |
| Verbet Group | ENT & Neurology / Oral Solids | Betahistine formulation used in the management of Meniere’s disease and vertigo disorders. |
Mapping the Domestic & Global Reach (India vs. Exports)
Albert David supplies formulation products across India and exports specialized generic drugs and APIs to international markets across Southeast Asia, Africa, the Middle East, and Latin America.
| Geographical Market | FY 2025-26 Revenue (₹ in Crores) | % Share of Total Sales | FY 2024-25 Revenue (₹ in Crores) | % Share of Total Sales | Latest YoY (%) |
|---|---|---|---|---|---|
| Domestic Market (India) | 309.59 | 94.00% | 320.04 | 93.24% | -3.27% |
| International / Export Markets | 19.78 | 6.00% | 23.20 | 6.76% | -14.74% |
| Total Gross Product Sales | 329.36 | 100.00% | 343.25 | 100.00% | -4.05% |
F.O.B. value of export earnings during FY 2025-26 stood at ₹17.07 Crores, compared to ₹20.26 Crores in FY 2024-25. International growth initiatives focus on expanding product registrations for Placentrex biomolecules, SSG injections, and Miltefosine in targeted CIS, Latin American, and African health ministries.
The Brick & Mortar Footprint: Manufacturing Plants, R&D & Offices
Albert David operates two primary manufacturing facilities in India:
- Kolkata Unit (West Bengal): Located at 5/11, D. Gupta Lane, Kolkata – 700050. Houses the primary production suite for Placentrex injections, topical gels, and creams, alongside specialized parenteral filling lines. Features an in-house Research & Development unit recognized by the Department of Scientific and Industrial Research (DSIR), Ministry of Science & Technology, since 2013. The Kolkata plant also utilizes solar power as an alternate energy source.
- Ghaziabad Unit (Uttar Pradesh): Located at B-12/13, Meerut Road, Industrial Area, Ghaziabad – 201003. An ISO 9001:2015 certified production plant equipped for high-volume manufacturing of Large Volume Parenterals (IV fluids), oral liquid syrups, and tablet/capsule packaging. In FY 2025-26, the unit completed modernisations to meet Revised Schedule M GMP standards.
📊 The Financial Health: Albert David Financial Statements & Numbers Simplified
Multi-Year Financial Highlights (₹ in Crores)
The multi-year financial summary below highlights Albert David’s top-line revenue trends, operating profitability, net earnings, and equity base over the past decade:
| Metric (₹ in Crores) | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 | Latest YoY (%) |
|---|---|---|---|---|---|---|---|---|---|
| Net Revenue from Sales | 3.29 | 3.43 | 3.60 | 3.40 | 3.12 | 2.46 | 3.18 | 3.13 | -4.08% |
| EBITDA (Operating Profit) | 12.92 | 32.61 | 104.43 | 59.74 | 56.64 | 36.33 | 37.43 | 50.50 | -60.38% |
| Profit / (Loss) Before Tax (PBT) | 0.52 | 25.23 | 97.29 | 50.74 | 47.30 | 27.44 | 28.95 | 42.86 | -97.94% |
| Profit / (Loss) After Tax (PAT) | -1.49 | 17.20 | 75.42 | 36.17 | 35.26 | 22.14 | 19.17 | 26.64 | N/M |
| Total Equity / Net Worth | 391.54 | 392.48 | 382.98 | 311.57 | 279.47 | 244.38 | 222.80 | 210.45 | -0.24% |
| Earnings Per Share (₹) | -2.62 | 30.14 | 132.15 | 63.39 | 61.78 | 38.80 | 33.59 | 46.68 | N/M |
| Dividend Payout (%) | 50.00% | 50.00% | 115.00% | 90.00% | 90.00% | 60.00% | 70.00% | 60.00% | – |
Earnings, Expenses, & Take-Home Profits (Standalone Profit & Loss)
The Statement of Profit and Loss reflects a year of operational transition. Revenue from Operations stood at ₹333.60 Crores in FY 2025-26, compared to ₹345.77 Crores in FY 2024-25. The decline in top-line revenue, combined with a reduction in Other Income (from ₹29.58 Crores to ₹7.45 Crores due to fair value adjustments on mutual fund investments) and upfront field force realignments, impacted net earnings for the fiscal year.
| Particulars (Ind AS Statement of Profit & Loss) | FY 2025-26 (₹ in Crores) | FY 2024-25 (₹ in Crores) | Latest YoY (%) |
|---|---|---|---|
| Revenue from Operations | 333.60 | 345.77 | -3.52% |
| Other Income | 7.45 | 29.58 | -74.81% |
| TOTAL INCOME | 341.05 | 375.35 | -9.14% |
| Cost of Materials Consumed | 59.89 | 70.15 | -14.63% |
| Purchases of Stock-in-Trade | 49.01 | 60.46 | -18.94% |
| Changes in Inventories of Finished Goods, WIP & Stock-in-Trade | 4.96 | -14.33 | N/M |
| Employee Benefits Expense | 102.48 | 109.02 | -6.00% |
| Finance Costs | 2.63 | 0.41 | +541.46% |
| Depreciation and Amortisation Expense | 9.76 | 6.97 | +40.03% |
| Other Expenses | 111.79 | 117.43 | -4.80% |
| EBITDA (Calculated Operating Profit before Tax, Int, Dep) | 12.92 | 32.61 | -60.38% |
| TOTAL EXPENSES | 340.53 | 350.12 | -2.74% |
| Profit / (Loss) Before Tax (PBT) | 0.52 | 25.23 | -97.94% |
| Current Tax Expense | 3.29 | 5.92 | -44.43% |
| Deferred Tax Expense / (Credit) | -1.28 | 2.10 | N/M |
| Profit / (Loss) After Tax (PAT) | -1.49 | 17.20 | N/M |
| Other Comprehensive Income / (Loss) (Net of Tax) | 3.40 | -1.14 | N/M |
| Total Comprehensive Income for the Year | 1.91 | 16.07 | -88.11% |
Assets, Borrowings, & Net Worth (Standalone Balance Sheet)
Albert David maintains a low-leverage balance sheet. As of March 31, 2026, total equity stood at ₹3.92 Crores, supported by cash, treasury investments, and fixed deposit balances totaling over ₹25.70 Crores.
| Balance Sheet Items (Ind AS Schedule III) | As at March 31, 2026 (₹ in Crores) | As at March 31, 2025 (₹ in Crores) | Latest YoY (%) |
|---|---|---|---|
| ASSETS | |||
| Property, Plant and Equipment | 99.07 | 97.71 | +1.39% |
| Capital Work-in-Progress (CWIP) | 20.77 | 1.73 | +1100.58% |
| Intangible Assets & Intangibles under Development | 0.58 | 1.26 | -53.97% |
| Non-Current Financial Investments | 18.23 | 17.95 | +1.56% |
| Other Non-Current Financial Assets | 2.72 | 38.09 | -92.86% |
| Other Non-Current Assets | 3.36 | 0.62 | +441.94% |
| Total Non-Current Assets | 144.73 | 157.36 | -8.03% |
| Inventories | 58.27 | 63.90 | -8.81% |
| Current Financial Investments (Mutual Funds & Bonds) | 225.05 | 242.21 | -7.08% |
| Trade Receivables | 33.92 | 27.37 | +23.93% |
| Cash and Cash Equivalents | 0.30 | 0.42 | -28.57% |
| Bank Balances other than Cash & Cash Equivalents | 32.47 | 1.28 | +2436.72% |
| Current Loans & Other Financial Assets | 6.13 | 8.69 | -29.46% |
| Current Tax Assets (Net) & Other Current Assets | 18.26 | 10.18 | +79.37% |
| Total Current Assets | 374.40 | 354.05 | +5.75% |
| TOTAL ASSETS | 519.13 | 511.42 | +1.51% |
| EQUITY AND LIABILITIES | |||
| Equity Share Capital | 5.71 | 5.71 | 0.00% |
| Other Equity (Reserves & Surplus) | 385.83 | 386.78 | -0.25% |
| Total Equity / Net Worth | 391.54 | 392.48 | -0.24% |
| Non-Current Lease Liabilities | 0.35 | 1.33 | -73.68% |
| Other Non-Current Financial Liabilities & Provisions | 6.74 | 7.10 | -5.07% |
| Deferred Tax Liabilities (Net) | 5.07 | 12.17 | -58.34% |
| Total Non-Current Liabilities | 12.17 | 14.75 | -17.49% |
| Current Borrowings (Short-Term Bank Debt) | 28.48 | 10.05 | +183.38% |
| Current Lease Liabilities | 0.75 | 0.94 | -20.21% |
| Trade Payables (MSME & Others) | 32.52 | 37.56 | -13.42% |
| Other Current Financial Liabilities & Provisions | 53.68 | 55.63 | -3.51% |
| Total Current Liabilities | 115.43 | 104.18 | +10.80% |
| Total Liabilities (Non-Current + Current) | 127.60 | 118.93 | +7.29% |
| TOTAL EQUITY AND LIABILITIES | 519.13 | 511.42 | +1.51% |
Working Capital Cycle & Schedule III Statutory Ratio Explanations
In accordance with Schedule III reporting guidelines, Albert David disclosed the following key financial ratios and variance analysis:
| Ratio Metric | FY 2025-26 | FY 2024-25 | % Variance | Management Explanation for Variance >25% | Latest YoY (%) |
|---|---|---|---|---|---|
| Debt-Equity Ratio (times) | 0.07 | 0.03 | -133.33% | Increase in working capital bank borrowings without a corresponding increase in equity to meet temporary fund requirements. | +133.33% |
| Current Ratio (times) | 3.24 | 3.40 | -4.93% | Maintained steady liquidity profile across operational assets. | -4.71% |
| Interest Coverage Ratio (times) | -1.85 | -17.87 | 89.64% | Impacted by higher short-term debt utilization and reduced net earnings during the fiscal year. | -89.65% |
| Inventory Turnover Ratio (times) | 10.00 | 12.22 | -18.17% | Marginal accumulation of finished formulations ahead of seasonal market dispatch. | -18.17% |
| Debtors’ Turnover Ratio (times) | 10.75 | 12.11 | -11.23% | Reflects stable collection cycles across wholesale stockist networks. | -11.23% |
| Operating Profit Margin (%) | -1.79% | -3.61% | 50.41% | Operational cost optimization partially offset gross margin pressure from material inputs. | – |
| Net Profit Margin (%) | 1.49 | 5.01% | -91.01% | Driven by lower product sales and a reduction in Other Income from mark-to-market mutual fund returns. | – |
| Return on Net Worth (%) | -0.38% | 6.27% | -93.93% | Impacted by the net loss recorded in FY 2025-26 relative to the ₹391.54 Crore net worth base. | – |
Cash Flow: Tracking the Money Movement
The Statement of Cash Flows outlines cash movements across operating, investing, and financing activities:
| Cash Flow Summary (Ind AS AS-7 Indirect Method) | FY 2025-26 (₹ in Crores) | FY 2024-25 (₹ in Crores) | Latest YoY (%) |
|---|---|---|---|
| Net Cash Generated / (Used) in Operating Activities | -7.66 | -28.44 | -73.07% |
| Purchase of PPE, CWIP & Intangibles (CapEx) | 29.11 | 14.86 | +95.90% |
| Sale of PPE & Realisation of Investments (Net) | 20.30 | 35.97 | -43.56% |
| Interest & Dividends Received | 4.15 | 3.62 | +14.64% |
| Net Cash Generated / (Used) in Investing Activities | -4.40 | 23.30 | N/M |
| Proceeds / (Repayment) of Short-Term Debt (Net) | 18.43 | 7.95 | +131.82% |
| Interest & Lease Liability Payments | -3.64 | -1.29 | +182.17% |
| Dividends Paid to Equity Shareholders | -2.86 | -6.55 | -56.34% |
| Net Cash Generated / (Used) in Financing Activities | 11.92 | 0.11 | +10736.36% |
| NET INCREASE / (DECREASE) IN CASH & CASH EQUIVALENTS | -0.14 | -5.02 | -97.21% |
| Opening Cash & Cash Equivalents | 0.42 | 5.44 | -92.28% |
| Closing Cash & Cash Equivalents at End of Year | 0.30 | 0.42 | -28.57% |
Funding the Future: CapEx, CWIP, R&D Intensity & Net Foreign Exchange
Capital expenditure additions during FY 2025-26 totaled ₹10.91 Crores in Property, Plant and Equipment, alongside ₹28.56 Crores directed into Capital Work-in-Progress (CWIP). CWIP projects stood at ₹20.77 Crores as of March 31, 2026, primarily comprising facility modernisations at the Kolkata SVP plant and the setup of the Miltefosine API manufacturing block.
Research and Development intensity remains an integral element of Albert David’s strategy:
- R&D Expenditure: Total revenue expenditure on R&D stood at ₹2.37 Crores in FY 2025-26 (0.71% of turnover), compared to ₹2.89 Crores (0.84% of turnover) in FY 2024-25.
- Foreign Exchange Outgo vs. Earnings: Foreign exchange earnings from exports totaled ₹17.07 Crores in FY 2025-26. Total foreign exchange outgo (on imports of raw materials, capital equipment, and foreign travel) stood at ₹25.08 Crores, resulting in a net foreign exchange utilization of ₹8.01 Crores.
👥 Power & Control: Albert David Governance, Leadership & Shareholding Pattern
The Brain Trust: Board of Directors & Key Managerial Personnel (KMP)
The Board of Directors of Albert David Limited comprises 8 members: 1 Executive Director, 2 Non-Executive Directors, and 5 Non-Executive Independent Directors.
| Name of Director / KMP | Designation / Role | DIN | Category |
|---|---|---|---|
| Mr. Arun Kumar Kothari | Executive Chairman | 00051900 | Promoter & Executive Director |
| Mrs. Prabhawati Devi Kothari | Non-Executive Director | 00051860 | Promoter & Non-Executive Director |
| Mr. Anand Vardhan Kothari | Non-Executive Director | 02572346 | Promoter & Non-Executive Director |
| Mr. Amit Mahla | Whole-time Director & CEO | 11767012 | Executive Director (Appointed w.e.f. June 19, 2026) |
| Mr. Anurag Singhi | Independent Director | 01807541 | Non-Executive Independent Director |
| Dr. Monjori Mitra | Independent Director | 02761691 | Non-Executive Independent Woman Director |
| Mr. Shourya Sengupta | Independent Director | 09216561 | Non-Executive Independent Director |
| Mr. Naresh Pachisia | Independent Director | 00233768 | Non-Executive Independent Director |
| Dr. Rajiv Anant Desai | Independent Director | 11193975 | Non-Executive Independent Director (Appointed w.e.f. August 2, 2025) |
| Mr. Ranadeep Bhattacharya | Chief Financial Officer (CFO) | – | Key Managerial Personnel |
| Mr. Lalit Lohia | Company Secretary & Compliance Officer | – | Key Managerial Personnel (ACS – 23995) |
Who Owns the Stock? Shareholding Pattern
The shareholding structure of Albert David Limited as of March 31, 2026, is detailed below:
| Shareholder Category | Number of Equity Shares Held | % of Total Issued Share Capital |
|---|---|---|
| Promoters & Promoter Group | 35,51,958 | 62.24% |
| Mutual Funds / UTI | 800 | 0.01% |
| Banks, Financial Institutions & Insurance Companies | 92,550 | 1.61% |
| Foreign Portfolio Investors (FPIs) | 33,249 | 0.58% |
| Domestic Corporate Bodies | 1,39,269 | 2.44% |
| Indian Public / Retail Shareholders | 15,66,353 | 27.45% |
| Non-Resident Indians (NRIs) | 54,877 | 0.96% |
| Clearing Members & Others | 2,22,202 | 3.89% |
| Investor Education & Protection Fund (IEPF) | 45,904 | 0.80% |
| Total Issued Equity Shares | 57,07,162 | 100.00% |
🗺️ The Corporate Family Tree: Group Structure, Ratings & Contingent Liabilities
Subsidiaries, Associates, & Joint Ventures (Form AOC-1)
Albert David Limited has no subsidiaries, associates, or joint venture entities. Consequently, reporting under Form AOC-1 is not applicable.
Strategic Investments, Credit Ratings, Banking Consortium & Contingent Liabilities
Albert David maintains treasury investments in non-current unquoted equity shares, corporate bonds, and debt/equity mutual funds:
- Non-Current Strategic Equity Holdings: Includes 8,42,472 equity shares of Bharat Fritz Werner Limited valued at ₹13.29 Crores; 1,90,000 equity shares of Kothari Phytochemicals & Industries Limited valued at ₹4.15 Crores; and 5,984 equity shares of Sunsure Solarpark Five Private Limited valued at ₹0.79 Crores.
- Credit Ratings: CARE Ratings re-affirmed its ratings for Albert David’s bank loan facilities: Long-Term Facilities rated CARE A (Stable); Short-Term Facilities rated CARE A1.
- Banking Consortium: Working capital and credit facilities are maintained with State Bank of India, ICICI Bank, and Bandhan Bank.
- Contingent Liabilities (Not Provided For): Outstanding claims and statutory disputes not acknowledged as debts as of March 31, 2026, totaled ₹4.68 Crores, including:
- Customs Duty Disputes: ₹2.54 Crores (under appeal before Commissioner of Customs).
- Water Pollution Cess / Other Legal Disputes: ₹2.05 Crores (pending before Lucknow High Court and other courts).
- Central Sales Tax & Excise Disputes: ₹0.09 Crores (pending before Kolkata High Court and CESTAT).
🎯 The Strategic Outlook: Competitive Moats, Risks, Growth Plans & FAQs
Competitive Advantages & Economic Moats
Albert David’s positioning rests on several core operational strengths:
- Regenerative Medicine Franchise (Placentrex Moat): Eight decades of clinical usage and continuous biomolecule research have built strong brand recall for Placentrex in tissue repair and chronic wound healing. The scientific identification of therapeutic nucleotides and peptides in partnership with IIT Kharagpur strengthens the company’s patent and clinical positioning.
- Integrated Manufacturing & Quality Approvals: ISO 9001:2015 certified facilities compliant with Revised Schedule M standards, complemented by WHO-Geneva Prequalification audit clearance for Sodium Stibogluconate (SSG).
- Institutional & Distribution Reach: A network of 2,500 stockists covering retail trade across India, supported by established bidding credentials for central and state government healthcare tenders.
- Strong Financial Net Worth & Capital Base: Net worth of ₹3.92 Crores with minimal long-term debt and liquid investments exceeding ₹25.70 Crores, providing financial flexibility to fund strategic expansions.
What Could Go Wrong? Key Challenges & Business Risks
Key operational and market risks facing the company include:
- Input Cost Volatility & Margin Pressure: Fluctuations in key active pharmaceutical ingredients (APIs), packaging materials, and energy costs can impact gross profit margins.
- Regulatory & Compliance Standards: Heightened oversight by the Central Drugs Standard Control Organisation (CDSCO) and international regulatory bodies requires continuous capital investment in plant quality systems and validation.
- Therapeutic Competition & Price Controls: Intense competition in large volume parenterals (IV fluids) and generic oral solids from domestic manufacturers, along with drug price cap adjustments under NLEM (National List of Essential Medicines).
- Foreign Exchange Exposure: Exposure to currency fluctuations (USD/INR and EUR/INR) on foreign currency trade payables and export realisations.
The Next Chapter: Growth, Order Pipeline & CapEx Initiatives
Albert David’s growth initiatives for FY 2026-27 focus on three primary pillars:
- Expanding the Placentrex Platform: Building a global patent portfolio around human placental biomolecules and scaling production across dermatological, surgical, and gynaecological prescribers.
- Commercialisation of Miltefosine API & Formulations: Scaling commercial batches of Miltefosine API and capsules from the new Kolkata factory block to fulfill domestic tenders and WHO global registration requirements for Kala-Azar treatment.
- Digitalization & Operational Efficiency: Enhancing field-force productivity through the HRMS platform OfficeNet and leveraging ERP systems (PROGEN) for supply chain tracking and working capital optimization.
The Verdict: Strategic Outlook & Conclusion
Albert David Limited enters its 88th year of operations with a debt-free balance sheet, an established product suite led by Placentrex, and modernised production units. While net profitability faced headwinds in FY 2025-26 due to field force realignments and investment valuation shifts, the company’s capital base, scientific partnerships with academic institutions, and WHO-compliant manufacturing infrastructure position it to execute its long-term growth plan across domestic healthcare and international markets.
Frequently Asked Questions (FAQs) About Albert David
Q1: What does Albert David Limited manufacture and what are its flagship brands?
Albert David Limited manufactures pharmaceutical formulations, small and large volume parenterals (IV fluids), herbal products, and active pharmaceutical ingredients (APIs). Its flagship brand is Placentrex (human placental extract injection, gel, and cream). Other top performing brands include Alamin SN, Alamin-M Forte, Evict, Sioplex-L, Adliv, Cyp-L, Verbet, and Sodium Stibogluconate (SSG) injection.
Q2: What were Albert David’s revenue and net profit in FY 2025-26?
In FY 2025-26, Albert David reported Standalone Revenue from Operations of ₹333.60 Crores (compared to ₹345.77 Crores in FY 2024-25). The company recorded a Net Loss after Tax of ₹1.49 Crores (compared to a Net Profit after Tax of ₹17.20 Crores in FY 2024-25), impacted by lower sales volume, commercial realignment expenses, and lower Other Income.
Q3: Who are the promoters and key executives of Albert David Limited?
Albert David belongs to the Kothari Group. Mr. Arun Kumar Kothari serves as the Executive Chairman. Effective May 12, 2026, Mr. Amit Mahla was appointed Chief Executive Officer (CEO) and subsequently designated Whole-time Director & CEO. Mr. Ranadeep Bhattacharya serves as Chief Financial Officer (CFO) and Mr. Lalit Lohia serves as Company Secretary & Compliance Officer.
Q4: Where are Albert David’s manufacturing plants located and what is its export footprint?
Albert David operates two manufacturing facilities: one in Kolkata (West Bengal) housing the Placentrex production hub, parenteral lines, and DSIR-recognized R&D center; and an ISO 9001:2015 certified unit in Ghaziabad (Uttar Pradesh) producing IV fluids and oral liquids. Exports accounted for ₹19.78 Crores (6.00% of sales) in FY 2025-26, reaching markets across Southeast Asia, Africa, the Middle East, and Latin America.
Q5: What is Albert David’s financial profile, debt position, and credit rating?
Albert David maintains a low-leverage capital structure. As of March 31, 2026, the company had a Net Worth of ₹3.92 Crores and short-term bank borrowings of ₹28.48 Crores against cash, bank balances, and mutual fund/bond investments exceeding ₹257 Crores. CARE Ratings has assigned a CARE A (Stable) rating for its long-term facilities and CARE A1 for short-term facilities.
Note: Financial ratios, margins, YoY growth percentages, and % revenue shares are calculated by IndianCompanies.in based on disclosed Ind AS financial statements.
Official Site: https://www.albertdavidindia.com